logo
  

Abbott Receives FDA Clearance For Cardiac Mapping System

Abbott (ABT) said that it has received clearance from the U.S. Food and Drug Administration for the EnSite X EP System with EnSite Omnipolar Technology, a new cardiac mapping platform available in the U.S. and across Europe that is designed to help physicians better treat abnormal heart rhythms, also known as cardiac arrhythmias.

The company noted that the system creates three-dimensional maps of the heart to help physicians identify and then treat areas of the heart where abnormal rhythms originate.

EnSite X EP System with EnSite Omnipolar Technology provides a 360-degree view of the heart, regardless of catheter orientation, for cardiac mapping without compromise.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Aerospace giant Boeing Co. (BA) on Wednesday reported fourth-quarter net loss attributable to Boeing shareholders of $4.16 billion or $7.02 per share, sharply narrower than $8.44 billion or $14.65 per share in the year-ago quarter. The 787 program recorded $3.5 billion pre-tax non-cash charge; focused... Telecom giant AT&T reported Wednesday a profit for the fourth quarter compared to a loss last year, primarily boosted by continuing customer growth in wireless, fiber and HBO Max, despite a 10 percent drop in revenues. Both adjusted earnings for the quarter and quarterly revenues also topped analysts' expectations. However, the company issued weak earnings and sales growth outlook for fiscal 2022. Bentley Motors, owned by German automaker Volkswagen AG, announced plans to develop its first-ever Battery-Powered Electric Vehicle or BEV in 2025. The British luxury carmaker also plans investment of around 2.5 billion pounds or $3.4 billion in sustainability over the next ten years. The company will develop and build the new vehicles in the UK plant in Crewe.
Follow RTT